Dual Strong Cyp3a4 / Moderate Cyp1a2 Inducers Interactions

Dual moderate CYP2C9/strong CYP3A4 inducers decrease siponimod exposure; concomitant use is not recommended.

Source: NLP:siponimod

Concomitant use not recommended as it may decrease VYKAT XR exposure and efficacy.

Source: NLP:diazoxide choline

Co-administration may increase roflumilast systemic exposure and may result in increased adverse reactions. Weigh potential for increased adverse reactions against benefit.

Source: NLP:roflumilast